Circulating tumor cells in cancer therapy: Are we off target?

Current Cancer Drug Targets

Volumn 10, Issue 5, 2010, Pages 509-518

  Raimondi, C ^a   Naso, G ^a   Gradilone, A ^a   Gianni, W ^b   Cortesi, E ^a   Gazzaniga, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INRCA   (Italy)

Author keywords

Chemotherapy; Circulating tumor cells; Drug resistance; Target therapy

Indexed keywords

ANTHRACYCLINE; CETUXIMAB; DEOXYCYTIDINE KINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; METHOTREXATE; PANITUMUMAB; THYMIDYLATE SYNTHASE; TOPOTECAN; TRASTUZUMAB; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CELL SURVIVAL; CLINICAL PRACTICE; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; OVERALL SURVIVAL; PHARMACOGENETICS; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SOLID TUMOR; TARGET CELL DESTRUCTION; TUMOR CELL; BLOOD; NEOPLASM; REVIEW; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 77956556246     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791517163     Document Type: Article

References (58)

1. Hüsemann, Y.; Geigl, J. B.; Schubert, F.; Musiani, P.; Meyer, M.; Burghart, E.; Forni, G.; Eils, R.; Fehm, T.; Riethmüller, G.; Klein, C. A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13, 58-68.
2. Bernards, R.; Weinberg, R. A. A progression puzzle. Nature 2002, 418, 823.
3. Pantel, K.; Brakenhoff, R. H. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004, 4, 448-456.
4. Alix-Panabieres, C.; Muller, V.; Pantel, K. Current status in human breast cancer micrometastasis. Curr. Opin. Oncol. 2007, 19, 558-563.
5. Mani, S. A.; Guo, W.; Liao, M. J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 2008, 133, 704-715.
6. Radisky, D. C.; LaBarge, M. A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2, 511-512.
7. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11, R46.
8. Amadori, A.; Rossi, E.; Zamarchi, R.; Carli, P.; Pastorelli, D.; Birillo A. Circulating and Disseminated Tumor Cells in the Clinical Management of Breast Cancer Patients: Unanswered Questions. Oncology 2009, 76, 375-386.
9. Pantel, K.; Brakenhoff, R. H.; Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8, 329-340.
10. Ring, A. E.; Zabaglo, L.; Ormerod, M. G.; Smith, I. E.; Dowsett, M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br. J. Cancer 2005, 92, 906-912.
11. Deng, G.; Herrler, M.; Burgess, D.; Manna, E.; Krag, D.; Burke, J. F. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008, 10, R69.
12. Mostert, B.; Sleijfer, S.; Foekens, J.; Gratama, J. Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treatment Reviews 2009, 35, 463-474.
13. Ignatiadis, M.; Georgoulias, V.; Mavroudis, D. Micrometastatic disease in breast cancer: clinical implications. Eur. J. Cancer 2008, 44, 2726-2736.
14. Cristofanilli, M.; Budd, G. T.; Ellis, M. J.; Stopeck, A.; Matera, J.; Miller, M. C.; Reuben, J. M.; Doyle, G. V.; Allard, W. J.; Terstappen, L. W.; Hayes, D. F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781-791.
15. Hayes, D. F.; Cristofanilli, M.; Budd, G. T.; Ellis, M. J.; Stopeck, A.; Miller, M. C.; Matera, J.; Allard, W. J.; Doyle, G. V.;Terstappen, L. W. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. Clin. Cancer Res. 2006, 12, 4218-4224.
16. Budd, G. T.; Cristofanilli, M.; Ellis, M. J.; Stopeck, A.; Borden, E.; Miller, M. C.; Matera, J.; Repollet, M.; Doyle, G. V.; Terstappen, L. W.; Hayes, D. F. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12, 6403-6409.
17. De Giorgi, U.; Valero, V.; Rohren, E.; Dawood, S.; Ueno, N. T.; Miller, M. C.; Doyle, G. V.; Jackson, S.; Andreopoulou, E.; Handy, B. C.; Reuben, J. M.; Fritsche, H. A.; Macapinlac, H. A.; Hortobagyi, G. N.; Cristofanilli, M. Circulating Tumor Cells and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J. Clin. Oncol. 2009, 27, 3303-3311.
18. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C. Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.
19. Cristofanilli, M.; Broglio, K. R.; Guarneri, V.; Jackson, S.; Fritsche, H. A.; Islam, R.; Dawood, S.; Reuben, J. M.; Kau, S. W.; Lara, J. M.; Krishnamurthy, S.; Ueno, N. T.; Hortobagyi, G. N.; Valero, V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer 2007, 6, 471-479.
20. Dawood, S.; Broglio, K.; Valero, V.; Reuben, J.; Handy, B.; Islam, R.; Jackson, S.; Hortobagyi, G. N.; Fritsche, H.; Cristofanilli, M. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008, 113, 2422-2430.
21. Meng, S.; Tripathy, D.; Shete, S.; Ashfaq, R.; Haley, B.; Perkins, S.; Beitsch, P.; Khan, A.; Euhus, D.; Osborne, C.; Frenkel, E.; Hoover, S.; Leitch, M.; Clifford, E.; Vitetta, E.; Morrison, L.; Herlyn, D.; Terstappen, L. W.; Fleming, T.; Fehm, T.; Tucker, T.; Lane, N.; Wang, J.; Uhr, J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA 2004, 101, 9393-9398.
22. Lang, J. E.; Mosalpuria, K.; Cristofanilli, M.; Krishnamurthy, S.; Reuben, J.; Singh, B.; Bedrosian, I.; Meric-Bernstam, F.; Lucci, A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res. Treat. 2009, 113, 501-507.
23. Pestrin, M.; Bessi, S.; Galardi, F.; Truglia, M.; Biggeri, A.; Biagioni, C.; Cappadona, S.; Biganzoli, L.; Giannini, A.; Di Leo, A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009, 118(3), 523-530.
24. Wülfing, P.; Borchard, J.; Buerger, H.; Heidl, S.; Zänker, K. S.; Kiesel, L.; Brandt, B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 2006, 12, 1715-1720.
25. Pierga, J. Y.; Bonneton, C.; Vincent-Salomon, A.; de Cremoux, P.; Nos, C.; Blin, N.; Pouillart, P.; Thiery, J. P.; Magdelénat, H. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 2004, 10, 1392-1400.
26. Gaforio, J. J.; Serrano, M. J.; Sanchez-Rovira, P.; Sirvent, A.; Delgado-Rodriguez, M.; Campos, M.; de la Torre, N.; Algarra, I.; Dueñas, R.; Lozano, A. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 2003, 107, 984-990.
27. Xenidis, N.; Perraki, M.; Kafousi, M.; Apostolaki, S.; Bolonaki, I.; Stathopoulou, A.; Kalbakis, K.; Androulakis, N.; Kouroussis, C.; Pallis, T.; Christophylakis, C.; Argyraki, K.; Lianidou, E. S.; Stathopoulos, S.; Georgoulias, V.; Mavroudis, D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 2006, 10, 3756-3762.
28. Zach, O.; Kasparu, H.; Wagner, H.; Krieger, O.; Lutz, D. Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med. Austriaca Suppl. 2002, 59, 32-34.
29. Stathopoulos, E. N.; Sanidas, E.; Kafousi, M.; Mavroudis, D.; Askoxylakis, J.; Bozionelou, V.; Perraki, M.; Tsiftsis, D.; Georgoulias, V. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann. Oncol. 2005, 16, 240-246.
30. Benoy, I. H.; Elst, H.; Philips, M.; Wuyts, H.; Van Dam, P.; Scharpé, S.; Van Marck, E.; Vermeulen, P. B.; Dirix, L. Y. Realtime RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br. J. Cancer 2006, 94, 672-680.
31. Ring, A.; Smith, I. E.; Dowsett, M. Circulating tumour cells in breast cancer. Lancet Oncol. 2004, 5, 79-88.
32. Pachmann, K.; Camara, O.; Kavallaris, A.; Krauspe, S.; Malarski, N.; Gajda M, Kroll T, Jörke, C.; Hammer, U.; Altendorf-Hofmann, A.; Rabenstein, C.; Pachmann, U.; Runnebaum, I.; Höffken, K. Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse. J. Clin. Oncol. 2008, 26, 1208-1215.
33. Ignatiadis, M.; Xenidis, N.; Perraki, M.; Apostolaki, S.; Poloitaki, E.; Kafousi, M.; Stathopoulos, E. N.; Stathopoulou, A.; Lianidou, E.; Chlouverakis, G.; Sotiriou, C.; Georgoulias, V.; Mavroudis, D. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J. Clin. Oncol. 2007, 25, 5194-5202.
34. Xenidis, N.; Ignatiadis, M.; Apostolaki, S.; Perraki, M.; Kalbakis, K.; Agelaki, S.; Stathopoulos, E. N.; Chlouverakis, G.; Lianidou, E.; Kakolyris, S.; Georgoulias, V.; Mavroudis, D. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 2009, 27, 2177-2184.
35. Pachmann, K.; Camara, O.; Kavallaris, A.; Schneider, U.; Schünemann, S.; Höffken, K. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res. 2005, 7, R975-R979.
36. Panteleakou, Z.; Lembessis, P.; Sourla, A.; Pissimissis, N.; Polyzos, A.; Deliveliotis, C.; Koutsilieris, M. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol. Med. 2009, 15, 101-114.
37. Scher, H. I.; Jia, X.; de Bono, J. S.; Fleisher, M.; Pienta, K. J.; Raghavan, D.; Heller, G.Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009, 10, 233-239.
38. Eschwège, P.; Moutereau, S.; Droupy, S.; Douard, R.; Gala, J. L.; Benoit, G.; Conti, M.; Manivet, P.; Loric, S. Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br. J. Cancer 2009, 100, 608-610.
39. Guller, U.; Zajac, P.; Bosch, B.; Vorburger, S.; Zuber, M.; Spagnoli, G. C.; Oertli, D.; Maurer, R.; Metzger, U.; Harder, F.; Heberer, M.; Marti, W. R. Disseminated single tumor cells as detected by real time polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colon cancer. Ann. Surg. 2002, 236, 768-775.
40. Uen, Y. H.; Lu, C. Y.; Tsai, H. L.; Yu, F. J.; Huang, M. Y.; Cheng, T. L.; Lin, S. R.; Wang, J. Y. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann. Surg. Oncol. 2008, 15, 2120-2128.
41. Cohen, S. J.; Punt, J. A.; Iannotti, N.; Saidman, B. H.; Sabbath, K. D.; Gabrail, N. Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, C.; Doyle, G.; Tissing, H. Relationship of circulating tumor cells to tumor response, progression free survival and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 3213-3221.
42. Sastre, J.; Maestro, M. L.; Puente, J.; Veganzones, S.; Alfonso, R.; Rafael, S.; García-Saenz, J. A.; Vidaurreta, M.; Martín, M.; Arroyo, M.; Sanz-Casla, M. T.; Díaz-Rubio, E. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 2008, 19, 935-938.
43. Uen, Y. H.; Lin, S. R.; Wu, D. C.; Su, Y. C.; Wu, J. Y.; Cheng, T. L.; Chi, C. W.; Wang, J. Y. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann. Surg. 2007, 246, 1040-1046.
44. Lankiewicz, S.; Zimmermann, S.; Hollmann, C.; Hillemann, T.; Greten, T. F. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol. Oncol. 2008, 2, 349-355.
45. Yen, L. C.; Yeh, Y. S.; Chen, C. W.; Wang, H. M.; Tsai, H. L.; Lu, C. Y.; Chang, Y. T.; Chu, K. S.; Lin, S. R.; Wang, J. Y. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res. 2009, 15, 4508-4513.
46. Molinari, F.; Martin, V.; Saletti, P.; De Dosso, S.; Spitale, A.; Camponovo, A.; Bordoni, A.; Crippa, S.; Mazzucchelli, L.; Frattini, M. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer 2009, 100, 1087-1094.
47. Gangemi, R.; Paleari, L.; Orengo, A. M.; Cesario, A.; Chessa, L.; Ferrini, S.; Russo, P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem. 2009, 16, 1688-1703.
48. Fotoohi, A. K.; Albertioni, F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk. Lymphoma 2008, 49, 410-426.
49. Koopman, M.; Venderbosch, S.; Nagtegaal, I. D.; van Krieken, J. H.; Punt, C. J. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur. J. Cancer 2009, 45, 1935-1949.
50. Allen, W. L.; Coyle, V. M.; Jithesh, P. V.; Proutski, I.; Stevenson, L.; Fenning, C.; Longley, D. B.; Wilson, R. H.; Gordon, M.; Lenz, H. J.; Johnston, P. G. Clinical determinants of response to irinote-can-based therapy derived from cell line models. Clin. Cancer Res. 2008, 14, 6647-6655.
51. Wilson, P. M.; Fazzone, W.; LaBonte, M. J.; Deng, J.; Neamati, N.; Ladner, R. D. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol. Cancer Ther. 2008, 7, 3029-3037.
52. Nakano, Y.; Tanno, S.; Koizumi, K.; Nishikawa, T.; Nakamura, K.; Minoguchi, M.; Izawa, T.; Mizukami, Y.; Okumura, T.; Kohgo, Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 2007, 96, 457-463.
53. Gennai, A.; Pronzato, P. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Clin. Breast Cancer 2008, 8, S179-183.
54. Bertazza, L.; Mocellin, S.; Nitti, D. Circulating tumor cells in solid cancer: tumor marker of clinical relevance? Curr. Oncol. Rep. 2008, 10, 137-146.
55. Gazzaniga, P.; Naso, G.; Gradilone, A.; Cortesi, E.; Gandini, O.; Gianni, W.; Fabbri, M. A.; Vincenti, B.; di Silverio, F.; Frati, L.; Aglianò, A. M.; Cristofanilli, M. Chemosensitivity profile assay of circulating cancer cells (CTCs): Prognostic and predictive value in epithelial tumors. Int. J. Cancer 2010, 126(10), 2437-2447.
56. Alunni-Fabbroni, M.; Sandri, M. T. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 2010, 50(4), 289-97.
57. Maheswaran, S.; Haber, D. A. Circulating tumor cells: a window into cancer biology and metastasis. Curr. Opin. Genet. Dev. 2010, 20(1), 96-99.
58. Bluemke, K.; Bilkenroth, U.; Meye, A.; Fuessel, S.; Lautenschlaeger, C.; Goebel, S.; Melchior, A.; Heynemann, H.; Fornara, P.; Taubert, H. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2190-2194.